Discontinued — last reported Q3 '22
Boston Scientific Acquisitions decreased by 65.2% to $89.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 97.4%, from $3.42B to $89.00M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -8.4% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $1.31B | $244.00M | $1.47B | $0.00 | $71.00M | $0.00 | $375.00M | $643.00M | $0.00 | $793.00M | $47.00M | $48.00M | $1.13B | $3.42B | $239.00M | $1.01B | $256.00M | $89.00M |
| QoQ Change | — | — | -81.3% | +502.9% | -100.0% | — | -100.0% | — | +71.5% | -100.0% | — | -94.1% | +2.1% | >999% | +203.3% | -93.0% | +322.2% | -74.6% | -65.2% |
| YoY Change | — | — | — | — | — | -94.6% | -100.0% | -74.5% | — | -100.0% | — | -87.5% | -92.5% | — | +331.0% | +408.5% | >999% | -77.3% | -97.4% |